TABLE 3.
Level of anti‐HBs after hepatitis B vaccine booster dose in 65 persons with anti‐HBs level <10 mIU/ml 35 years after a primary hepatitis B vaccination series—Alaska 2016–2017
| Characteristic | N (%) of cohort | Anti‐HBs level (mIU/ml) | p value a | |
|---|---|---|---|---|
| GMC | % With ≥10 (N) | |||
| Overall | 65 | 91.3 | 78.5 (51) | |
| Sex | ||||
| Female | 34 (52.3) | 79.3 | 82.4 (28) | 0.42 |
| Male | 31 (47.7) | 106.7 | 74.2 (23) | |
| Age at booster vaccination (age at primary vaccination), years | ||||
| <40 (<5) | 12 (18.5) | 74.1 | 83.3 (10) | 0.50 |
| 40 to <45 (5 to <10) | 11 (16.9) | 235.0 | 81.8 (9) | |
| 45 to <55 (10 to <20) | 27 (41.5) | 79.0 | 77.8 (21) | |
| ≥55 (≥ 20) | 15 (23.1) | 70.1 | 73.3 (11) | |
| Anti‐HBs level after primary series, mIU/ml | ||||
| 10–199 | 11 (16.9) | 9.8 | 27.3 (3) | <0.001 b |
| 200–499 | 15 (23.1) | 46.5 | 80.0 (12) | |
| 500–999 | 13 (20.0) | 45.8 | 76.9 (10) | |
| ≥1000 | 26 (40.0) | 488.7 | 100.0 (26) | |
| Preboost Anti‐HBs, mIU/ml | ||||
| 0 to <2 | 37 (56.9) | 29.1 | 64.9 (24) | 0.0021 |
| 2 to <5 | 10 (15.4) | 225.6 | 90.0 (9) | |
| 5 to <10 | 18 (27.7) | 581.2 | 100.0 (18) | |
| Follow‐up group | ||||
| Did not participate in 22‐ or 30‐year follow‐up (group 1) | 38 (58.5) | 58.7 | 73.7 (28) | 0.26 |
| Did participate in 22‐ or 30‐year follow‐up (group 2) | 27 (41.5) | 170.2 | 85.2 (23) | |
a
Tested using the likelihood‐ratio chi‐square test with sufficient numbers. Fisher’s exact test was performed when expected counts were <5. The Cochran‐Armitage trend test was used to analyze anti‐HBs levels after the HBV primary series and preboost anti‐HBs.
b
After adjustment for anti‐HBs level after primary series, no other variables were statistically significant.